全文获取类型
收费全文 | 17801篇 |
免费 | 1242篇 |
国内免费 | 32篇 |
专业分类
耳鼻咽喉 | 277篇 |
儿科学 | 498篇 |
妇产科学 | 593篇 |
基础医学 | 2152篇 |
口腔科学 | 260篇 |
临床医学 | 2522篇 |
内科学 | 3097篇 |
皮肤病学 | 324篇 |
神经病学 | 1478篇 |
特种医学 | 690篇 |
外国民族医学 | 1篇 |
外科学 | 1734篇 |
综合类 | 202篇 |
一般理论 | 27篇 |
预防医学 | 2522篇 |
眼科学 | 180篇 |
药学 | 1138篇 |
中国医学 | 10篇 |
肿瘤学 | 1370篇 |
出版年
2023年 | 101篇 |
2022年 | 163篇 |
2021年 | 307篇 |
2020年 | 226篇 |
2019年 | 349篇 |
2018年 | 409篇 |
2017年 | 307篇 |
2016年 | 323篇 |
2015年 | 344篇 |
2014年 | 505篇 |
2013年 | 724篇 |
2012年 | 1106篇 |
2011年 | 1028篇 |
2010年 | 579篇 |
2009年 | 568篇 |
2008年 | 1005篇 |
2007年 | 1067篇 |
2006年 | 1038篇 |
2005年 | 1059篇 |
2004年 | 967篇 |
2003年 | 968篇 |
2002年 | 893篇 |
2001年 | 308篇 |
2000年 | 249篇 |
1999年 | 291篇 |
1998年 | 207篇 |
1997年 | 180篇 |
1996年 | 184篇 |
1995年 | 137篇 |
1994年 | 135篇 |
1993年 | 122篇 |
1992年 | 197篇 |
1991年 | 210篇 |
1990年 | 195篇 |
1989年 | 209篇 |
1988年 | 167篇 |
1987年 | 155篇 |
1986年 | 149篇 |
1985年 | 158篇 |
1984年 | 157篇 |
1983年 | 128篇 |
1982年 | 124篇 |
1981年 | 96篇 |
1980年 | 97篇 |
1979年 | 126篇 |
1978年 | 106篇 |
1975年 | 80篇 |
1974年 | 92篇 |
1973年 | 85篇 |
1971年 | 78篇 |
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
1.
2.
3.
4.
Fiene Marie Kuijper Uma V. Mahajan Seul Ku Daniel A.N. Barbosa Sheila M. Alessi Sherman C. Stein Kyle M. Kampman Brandon S. Bentzley Casey H. Halpern 《Neuromodulation》2022,25(2):253-262
ObjectivesCocaine is the second most frequently used illicit drug worldwide (after cannabis), and cocaine use disorder (CUD)-related deaths increased globally by 80% from 1990 to 2013. There is yet to be a regulatory-approved treatment. Emerging preclinical evidence indicates that deep brain stimulation (DBS) of the nucleus accumbens may be a therapeutic option. Prior to expanding the costly investigation of DBS for treatment of CUD, it is important to ensure societal cost-effectiveness.AimsWe conducted a threshold and cost-effectiveness analysis to determine the success rate at which DBS would be equivalent to contingency management (CM), recently identified as the most efficacious therapy for treatments of CUDs.Materials and MethodsQuality of life, efficacy, and safety parameters for CM were obtained from previous literature. Costs were calculated from a societal perspective. Our model predicted the utility benefit based on quality-adjusted life-years (QALYs) and incremental-cost-effectiveness ratio resulting from two treatments on a one-, two-, and five-year timeline.ResultsOn a one-year timeline, DBS would need to impart a success rate (ie, cocaine free) of 70% for it to yield the same utility benefit (0.492 QALYs per year) as CM. At no success rate would DBS be more cost-effective (incremental-cost-effectiveness ratio <$50,000) than CM during the first year. Nevertheless, as DBS costs are front loaded, DBS would need to achieve success rates of 74% and 51% for its cost-effectiveness to exceed that of CM over a two- and five-year period, respectively.ConclusionsWe find DBS would not be cost-effective in the short term (one year) but may be cost-effective in longer timelines. Since DBS holds promise to potentially be a cost-effective treatment for CUDs, future randomized controlled trials should be performed to assess its efficacy. 相似文献
5.
6.
7.
Janet Fricke Carolyn Unsworth Diane Worrell 《Australian Occupational Therapy Journal》1993,40(1):7-15
This paper reports an inter-rater reliability study on the Functional Independence Measure (FIM). The FIM measures inpatient burden of care, as reflected in 18 self care items, rated on a seven point scale from dependent to independent. The subjects were 40 occupational therapists, divided according to experience with the FIM and randomly assigned to a FIM training or non-training group. Subjects rated video tapes of four stroke patients on transfers, bathing, dressing, grooming, toileting and eating items from the FIM. Rater consensus was calculated using the intraclass correlation coefficient (ICC), percentage agreement and a measure of disagreement. Rating accuracy was measured by comparisons with an expert rater. Ratings were most reliable when done by clinicians with no prior FIM experience, from the FIM training group. It is strongly recommended that all clinicians undergo FIM training before using this tool to ensure acceptable reliability. 相似文献
8.
9.
Etiological heterogeneity in Hodgkin's disease: HLA linked and unlinked determinants of susceptibility independent of histological concordance 总被引:2,自引:0,他引:2
Forty-one multiplex families, from published sources and new data from the National Cancer Institute, segregating for Hodgkin's disease and HLA, have been studied. A reanalysis of these data strongly suggests a recessive mode of inheritance for susceptibility to Hodgkin's disease. The HLA haplotype sharing data between affected relatives demonstrate that approximately 60% of cases in multiplex families are due to an HLA-linked susceptibility gene, the remaining 40% being due to other familial factors. The data clearly support the hypothesis of etiological heterogeneity for Hodgkin's disease, with both HLA-linked and HLA-unlinked factors being responsible. Finally, there is an increased concordance of histological types between affected relatives, but this concordance seems independent of HLA sharing. 相似文献
10.